A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL

Project: Research

Project Details

Project Description

NMA HREC Reference Number: SVHS 2020/ETH00036
NMA SSA Reference Number: SSA/65008/MonH-2020-219898(v1)
Monash Health Reference: RES-20-0000-465X
Effective start/end date9/07/208/07/25


  • phase 3 study
  • clinical trial
  • treatment safety
  • treatment efficacy
  • HIV